Introduction
============

Hypoxic-ischemic brain damage (HIBD) in neonates involves the cerebral injury of fetus and neonates caused by partial or complete hypoxia, cerebral blood flow reduction or pause, which is caused by perinatal asphyxia ([@b1-etm-0-0-3411]). HIBD often occurs within 24 h after birth, and the occurrence rate of hypoxic ischemic encephalopathy (HIE) in neonates is 3--6‰ of live births. There are different types and different degrees of long-term sequelae in 25--30% of live births, which is the important disease that affects the life quality of children ([@b2-etm-0-0-3411]). The diagnosis is based on consciousness, muscular tension, change of primitive reflex, convulsion, disease course and prognosis. HIBD is divided into mild, moderate and severe degrees, however, laboratory tests for diagnosis are currently insufficient.

Hypoxia ischemia can activate a series of biological chain reactions including affecting the oxidative phosphorylation of glucose, rapid depletion of ATP in cells, accumulation of lactic acid, depolarization of cell membrane, release of excitatory amino acid and accumulation of Na^+^, Ca^2+^, H~2~O, free radical and free fatty acid (FFA) in cells, to cause cellular swelling and cell death ([@b3-etm-0-0-3411]). Hypoxia ischemia can decrease the synthesis of protein and adipose and increase their metabolic products such as urea nitrogen, creatinine, uric acid and FFA. Adipocyte fatty acid-binding protein (A-FABP) is a member of the fatty acid binding protein family. It is expressed in adipocytes and macrophages, as well as endothelial cells and blood. As a molecular chaperone of fatty acid, A-FABP is considered a thrifty gene that can promote the transfer of fatty acid and energy storage. When the body experiences stress such as starvation, the preserved energy is released for body utilization. A-FABP is an important regulatory factor of obesity, insulin resistance and metabolic syndrome and the expression of A-FABP can be induced by proliferator-activated receptor γ (PPARγ) agonist, insulin and fatty acid ([@b4-etm-0-0-3411]). However, the role and significance of A-FABP in HIBD have yet to be studied universally. As the hypoxia ischemia lengthens, the level of FFA increases in neonates with HIBD, and it is suggested that increased FFA can induce the expression of A-FABP to cause an increase of serum A-FABP.

In the present study, serum levels of A-FABP and FFA in 42 neonates with acute phase and recovery phase HIBD were detected, respectively, using the enzyme-linked immunosorbent assay (ELISA) and copper colorimetric method. The relationship between A-FABP, FFA level and severity of HIBD was analyzed, and the change of the above indicators in the same neonate at the acute and recovery phase was observed. The aim was to explore the relationship between A-FABP, FFA and severity of HIBD with acute phase and provide a diagnostic basis for diagnosis and prognosis of HIBD.

Patients and methods
====================

### Patients

In total 42 full-term neonates with HIBD admitted between January 2009 and January 2010 at the Department of Pediatric, Fourth Hospital of Hebei Medical University (Hebei, China) and Department of Pediatric, Cangzhou Central Hospital (Cangzhou, China) were selected. There were 31 male and 11 female cases, 17 cases of eutocia and 25 cases of cesarean delivery. The average gestational age was 38.8±1.33 weeks, and the average weight was 3.15±0.51 kg at birth.

### Criteria of diagnosis and clinical grading

The criteria of diagnosis and clinical stage used were as reported earlier ([@b5-etm-0-0-3411]). The neonate based on the following criteria were diagnosed as HIE: i) There was confirmed abnormal obstetric history causing fetal distress in the uterus, and severe fetal distress manifestation (fetal heart rate \<100/min for \>5 min; and/or degree III amniotic fluid pollution) or obvious asphyxia history during delivery; ii) there was severe asphyxia during delivery, i.e. Apgar score ≤3 at 1st min, ≤5 at 5th min; and/or pH ≤7.0 in blood gas of umbilical artery; iii) there were neurological symptoms after birth, that persisted for \>24 h, such as change of consciousness (over excitation, somnolence, coma), change of muscular tension (increase or decrease), abnormity of primitive reflexes (sucking reflex or moro reflex was weakened or disappeared), convulsion and brain stem symptom when seriously ill (change of respiratory rhythm, change of pupil, light reflex was slow or disappeared) and increase of bregma tension; and iv) the neonates with convulsion caused by electrolyte disturbance, intracranial hemorrhage and birth injury were excluded. The neonates with brain injury caused by intrauterine infection, genetic metabolic disease or other congenital diseases were excluded.

In addition, if by computed tomography scan there was encephaledema, there was diffuse low-density shadow complicated with narrowed encephalocoele in brain parenchyma. If basal ganglia and thalamus were injured there was bilateral symmetric high-density shadow, while the cerebral infarction showed low-density shadow in the corresponding blood supply area. The clinical grading of HIE is shown in [Table I](#tI-etm-0-0-3411){ref-type="table"}.

### Inclusion criteria

i\) Neonates were full-term (gestational age was between 37 and 42 weeks, birth weight between 2,500--4,000 g), Apgar score of included neonates at 1st min was \>3; ii) neonates did not receive cortical hormone treatment. The remaining inclusion criteria were the same as those for HIE. In total, 11 included cases were mild, 16 included cases were moderate and 15 included cases were severe.

### Control group

Ten cases of neonates with similar gestational age and weight to the HIBD group were selected from the full-term neonates without hypoxia manifestation and cardiopulmonary disease at the same period. There were 7 male cases and 3 female cases, 4 cases of eutocia and 6 cases of cesarean delivery, the average gestational age was 38.5±1.12 weeks, the average weight was 3.29±0.52 kg at birth (Apgar score was 9′-10′-10′ or 10′-10′-10′).

### Methods

#### Serum collection

Blood (2--3 ml) was collected from peripheral vein in HIBD and normal neonates within 72 h after the first visit and at 7 days after birth. The blood was routinely centrifuged at 1,000 × g for 5 min to collect serum and later preserved at −20°C. The indicators in HIBD and normal neonates were detected at the same time. Informed consent was obtained from the families of neonates for serum collection.

#### Detection of serum A-FABP by ELISA

The reagent kit was provided by Adlitteram Diagnostic Laboratories (San Diego, CA, USA), and plate washing and absorbance detection were completed on a microplate reader. A-FABP standard solution (100 µl), serum (100 µl) and 50 µl biotin-labeled A-FABP with specific anti A-FABP antibody-coated micropores were mixed. After incubation at 37°C for 1 h, the plates were washed for 55 min, 50 µl horse radish peroxidase-conjugated anti-biotin antibody and 50 µl enzyme substrate solution were added for developing coloration. After 15 min the stopping buffer was added to terminate the reaction, and then optical density (OD) values of different wells were read at a wavelength of 450 nm. B was the OD value of standard and B0 was the OD value of standard at time point 0. The B/B0% value was set as a vertical coordinate and the concentration of standard was set as a horizontal coordinate to make a standard curve on the logarithmic coordinate paper. The concentration of A-FABP was determined according to the OD value of the sample on the standard curve.

#### Detection of FFA by copper colorimetric method

The copper colorimetric method was used to detect FFA according to the kit instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

#### Detection of white blood cell, blood lipid, glucose and C-reactive protein

White blood cell, blood lipid, glucose and C-reactive protein were detected by Beckman Coulter LH 750, Beckman Coulter LX20 PRO detection and Beckman Immade detection (Beckman Coulter, Inc., Brea, CA, USA).

#### Statistical analysis

Data were analyzed using SPSS 11.5 (SPSS, Inc., Chicago, IL, USA). The data received normal distribution test (Kolmogorov-Smirnov test), normal distributional data were presented as mean ± standard deviation, and the difference was analyzed by t-test and variance analysis. Non-normal distributional data were presented as median (25 percentile, 75 percentile), the difference was analyzed by the rank sum test and the inspection level was a=0.05. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical data

The gender composition, the proportion of cesarean delivery, average gestational age, and birth weight in three HIBD neonate groups were not statistically different compared to normal neonates ([Table II](#tII-etm-0-0-3411){ref-type="table"}).

### White blood cell count and serum C-reactive protein (CRP) in HIBD neonates at acute stage

The white blood cell count in HIBD neonates (16.27±1.26×10^9^/l) was significantly higher than that of normal neonates (8.53±2.98×10^9^/l) (P\<0.01). However, serum CRP in HIBD and normal neonates were in the normal range (CRP \<8 mg/l) (in both groups, the infectious factor was excluded, the increase of white blood cell count in HIBD neonates was considered to be related to the stress reaction caused by hypoxia ischemia) ([Table III](#tIII-etm-0-0-3411){ref-type="table"}).

### Blood lipid and glucose levels in HIBD neonates at acute stage

High-density lipoprotein (HDL) level in HIBD neonates (0.65±0.23 mmol/l) was significantly decreased compared with normal neonates (0.81±0.18 mmol/l) (P\<0.01). The other blood lipid parameters and blood glucose level were not different from normal neonates ([Table IV](#tIV-etm-0-0-3411){ref-type="table"}).

### Serum A-FABP level in HIBD neonates at acute stage

Serum A FABP content in overall HIBD neonates at acute stage was 21.61 (14.96, 37.67) ng/l, which was significantly higher than 13.41 (9.64, 17.46) ng/l in the normal neonates (P\<0.05). The serum A-FABP level in severe HIBD neonates was significantly higher than mild HIBD, moderate HIBD and normal neonates (P\<0.05). There was no difference between the mild HIBD and moderate HIBD neonates ([Fig. 1](#f1-etm-0-0-3411){ref-type="fig"}).

### Serum FFA level in HIBD neonates at acute stage

The overall serum FFA level in HIBD neonates at the acute stage was significantly higher than that of normal neonates (P\<0.05). The serum FFA levels in mild, moderate and severe HIBD neonates were significantly higher than those of normal neonates (P\<0.05). However, serum FFA level was not different among mild, moderate and severe HIBD neonates ([Fig. 2](#f2-etm-0-0-3411){ref-type="fig"}).

### Changes of A-FABP and FFA levels at recovery stage compared with acute stage

The overall A-FABP in HIBD neonates at the recovery stage was significantly decreased compared to the acute stage (P\<0.05), which was significant in severe HIBD neonates (P\<0.05). A-FABP levels in the mild and moderate HIBD neonates at recovery stage were decreased compared with the acute stage, however there was no statistical difference ([Fig. 3](#f3-etm-0-0-3411){ref-type="fig"}). The overall FFA content in HIBD neonates at the recovery stage was decreased, however there was no statistical difference compared to the acute stage.

### Correlation of serum A-FABP and FFA in HIBD neonates at the acute and recovery stages

Serum A-FABP level and FFA levels in HIBD neonates at the acute stage were positively correlated, with the correlation coefficient as r=0.369 (P\<0.05). However, there was no correlation at the recovery stage ([Figs. 4](#f4-etm-0-0-3411){ref-type="fig"}--[6](#f6-etm-0-0-3411){ref-type="fig"}).

Discussion
==========

HIBD of neonates is important in perinatal nervous system disease, and severe HIBD neonates leads to serious complications of non-reversible nervous system sequelae. Hypoxia is the key link of pathogenesis, while a series of cascade reactions follow hypoxia. Interactions of several mechanisms cause degeneration and necrosis, even softening of brain tissue and further induce non-reversible brain injury ([@b6-etm-0-0-3411]). Statistics indicate 18--20 million live neonates, and the occurrence rate of HIE as \~3--6‰ of live neonates, 15--20% of whom die at the neonatal period, while different types and degrees of long-term sequelae are present in 25--30% of survivals. Thus, this disease affects the quality of life of children ([@b2-etm-0-0-3411]). At present, the diagnosis of HIBD has been primarily based on medical history, clinical manifestation, blood gas analysis and imageological examination. Certain criteria ([@b7-etm-0-0-3411]) are apparently extremely rigid, without flexibility, leading to an appropriate diagnosis. The diagnostic criteria at home and abroad lack objective and effective laboratory examination, affecting the early diagnosis and appropriate observation of the degree of injury and therapeutic effects in HIBD neonates ([@b8-etm-0-0-3411]).

When there is hypoxia ischemia, the cell membrane of neurons is depolarized and intracellular Ca^2+^ concentration is rapidly increased. Hypoxia ischemia can cause the release of a large number of oxygen radicals and the participation of free radicals can degrade membrane phospholipid to release a large number of FFA ([@b9-etm-0-0-3411]). It has been found that phospholipase is activated and FFA is released in moderate and severe asphyxia Wistar rat ([@b10-etm-0-0-3411]). FFA level in the cerebral cortex in HIBD neonates becomes elevated with prolonging of the hypoxia ischemia ([@b11-etm-0-0-3411]). In the present study, serum FFA content level in HIBD neonates at acute stage was significantly higher than that in normal neonates, and the serum FFA level was also increased with aggravation of the degree of hypoxia Overall serum FFA and FFA levels in moderate and severe neonates was reduced, whereas serum FFA was increased in the mild neonates. Considering that the symptoms of mild HIBD neonates were rapidly recovered and the body weight increased satisfactorily, FFA increase may be affected by sufficient diet, breast milk or powered milk.

A-FABP mainly exists in adipocytes and macrophages, the main function of which is to regulate lipid metabolism. It regulates oxidation of fatty acid and metabolism of phospholipid and triglyceride in several steps including assimilation, convey, esterification and β oxidation ([@b12-etm-0-0-3411]). PPARγ activator, insulin, FFA and oxidized low-density lipoprotein can upregulate A-FABP expression ([@b13-etm-0-0-3411],[@b14-etm-0-0-3411]). A-FABP gene knockout mice manifest as increased fat, decreased lipolysis, increased aerobic oxidation and reduced insulin resistance, indicating that A-FABP regulates energy metabolism by regulating fatty acid metabolism ([@b15-etm-0-0-3411]). Considering that the long-chain FFA can induce the expression of A-FABP, we hypothesized that if FFA was increased in HIBD neonates, A-FABP expression would also be increased in HIBD neonates. In the present study, the results verified the hypothesis as the overall serum A-FABP in HIBD neonates at acute stage was significantly higher than that in normal neonates. Serum A-FABP level in severe HIBD neonates was significantly higher than than in mild and moderate HIBD neonates. The overall A-FABP in HIBD neonates at the recovery stage was significantly decreased compared to the acute stage, which was significant in severe HIBD neonates. The overall serum A-FABP and FFA levels in HIBD neonates at the acute stage were positively correlated.

In 2006, A-FABP was initially identified as a blood circulation protein ([@b16-etm-0-0-3411]). However, there is no specific basis that verifies that A-FABP is released by adipocytes and macrophages or regulated by some regulatory mechanism. Additionally, there was secretion signal sequence in the primary and tertiary structures of A-FABP ([@b17-etm-0-0-3411],[@b18-etm-0-0-3411]). It was shown that the protein lacking the exocytosis positioning signal sequence can pass plasma membrane by an unconventional secretion mechanism ([@b19-etm-0-0-3411]). Rat adipocytes lack secretion signal sequences, the release of various proteins was completed by vesicle in rat, and A-FABP was found in vesicle ([@b20-etm-0-0-3411]). There was also A-FABP in the vesicle fragment of human cell supernatant ([@b21-etm-0-0-3411]). The abovementioned results have shown that at least part of A-FABP can enter the blood circulation by vesicle of adipocytes. Although the mechanism of how FABP4 enters blood circulation remains to be determined, it has been demonstrated that A-FABP was significantly increased in patients with lipid metabolic diseases such as simple obesity, metabolic syndrome ([@b22-etm-0-0-3411],[@b23-etm-0-0-3411]), familial hyperlipidemia ([@b24-etm-0-0-3411]), non-alcoholic cirrhosis ([@b25-etm-0-0-3411]) and coronary heart disease ([@b26-etm-0-0-3411],[@b27-etm-0-0-3411]). Recent findings have shown that although there was no A-FABP in the endothelial cells of small cerebral vessels, there was A-FABP in endothelial cells of blood capillaries and small veins in myocardium, skeleton muscles and tissue beside the large airway ([@b28-etm-0-0-3411]). Thus we considered that endothelial cells were one source of blood FABP4.

Different results have been identified regarding blood lipid level in asphyxia neonates. In the detection of blood lipid leveld in hypoxia asphyxia neonates by Yu *et al* ([@b29-etm-0-0-3411]), serum total cholesterol and triglyceride were significantly increased at the early stage of asphyxia, which was more significant in severe neonates. Time-course of the blood lipid level in asphyxia neonates, triglyceride (TG) and apolipoprotein A1 levels were significantly increased after birth, while HDL cholesterol (HDL-C) was decreased. This finding was not related to asphyxia degree, and there was no significant change of other indicators ([@b30-etm-0-0-3411]). In the present study, TG was increased and HDL-C was decreased in the HIBD neonates. These results indicate that although there was dyslipidemia in HIBD neonates, the conventional lipid detection cannot be applied as a specific laboratory indicator for HIBD. Serum FFA and FABP4 were significantly increased in HIBD neonates at the acute stage, which were increased with the increase in degree of injury, and decreased as the recovery of disease condition.

In conclusion, the results have shown that serum FFA and A-FABP were increased in HIBD neonates at the acute stage, and the serum level of A-FABP and FFA at acute stage can reflect the severity of HIBD. The detection of serum A-FABP and FFA cannot only be applied as the indicators for the early diagnosis of HIBD, but also provides a basis for the clinical evaluation of HIBD treatment.
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###### 

The clinical grading of hypoxic ischemic encephalopathy.

                                                                                                    Primitive reflex                                                                                                                                                  
  ---------- ------------------------------------------ ------------------------------------------- ------------------ ------------- ------------------------ --------- ------------------------------------------- ------------------------------------------------- -----------------------------------------------------------------------------------------
  Mild       Alternating of excitement and inhibition   Normal or slightly increased                Active             Normal        Myoclonus sometimes      No        Normal or enlarged                          Normal                                            Symptoms disappear within 72 h with good prognosis
  Moderate   Somnolence                                 Decreased                                   Weakened           Weakened      Often                    Yes       Often diminished                            Low voltage, complicated epileptiform discharge   Symptoms disappear within 14 days with possible sequelae
  Severe     Coma                                       Floppy or intermittent muscular increased   Disappeared        Disappeared   Yes, can be persistent   Obvious   Asymmetric or enlarged, slow light reflex   Burst, suppression isoelectric line               Symptoms persist for several weeks, the mortality is high, most survivals have sequelae

EEG, encephalographic.

###### 

Clinical parameters of HIBD and normal neonates.

  Group       Control     Case        Mild        Moderate    Severe      F       P-value
  ----------- ----------- ----------- ----------- ----------- ----------- ------- ---------
  No.         10          42          11          16          15                  
  FA, weeks   38.5±1.12   38.8±1.33     39±1.35   38.5±1.22   38.7±1.29   0.759   \>0.05
  BW, kg      3.29±0.52   3.15±0.51   2.94±0.55   3.10±0.35   3.37±0.56   1.914   \>0.05
  Male        7           31          7           12          12                  \>0.05
  Female      3           11          4             4           3                 \>0.05
  Eutocia     4           17          6             4           7                 \>0.05
  U-D         6           25          5           12            8                 \>0.05

The comparison is made with one-way ANOVA and two-independent sample tests (Mann-Whitney U). FA, fatal; BW, body weight; HIBD, hypoxic-ischemic brain damage.

###### 

Count of WBC and the content of C-reactive protein in the acute stage of the HIBD and normal neonates.

  Group            Control     Case         t-test   P-value
  ---------------- ----------- ------------ -------- ---------
  No.              10          42                    
  WBC (×10^9^/l)   8.53±2.98   16.27±1.26   −4.919   \<0.01
  CRP (mg/l)       \<8         \<8                   \>0.05

The comparison is made with the independent-samples t-test. WBC, white blood cell; HIBD, hypoxic-ischemic brain damage; CRP, C-reactive protein.

###### 

Levels of blood-lipid and BG in acute stage of HIBD and normal neonates.

  Group         Control             Case                t/z      P-value
  ------------- ------------------- ------------------- -------- ---------
  No.           10                  42                           
  TC, mmol/l    2.72±0.97           2.42±0.89           0.941    \>0.05
  TG, mmol/l    0.57 (0.29--0.80)   0.60 (0.37--1.15)   −0.965   \>0.05
  HDL, mmol/l   0.81±0.18           0.65±0.23           2.037    \<0.05
  LDL, mmol/l   1.45±0.70           1.19±0.55           1.254    \>0.05
  ApoA, g/l     0.80 (0.60--0.85)   0.71 (0.70--0.80)   −0.649   \>0.05
  ApoB, g/l     0.33±0.16           0.35±0.14           −0.232   \>0.05
  BG, mmol/l    3.90±1.12           3.35±1.20           1.207    \>0.05

The comparison is made with the independent-samples t-test. HIBD, hypoxic-ischemic brain damage; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Apo, apolipoprotein; BG, blood glucose.
